Scienture Holdings Inc
Scienture Holdings Inc has a market capitalization of $16.7 million and a price-to-earnings ratio of 0.79, indicating a relatively low valuation compared to earnings. The company's price-to-book ratio is 1.23, suggesting that the market value is slightly above the book value of its equity. The company's liquidity position is characterized by a current ratio of 4.75, which is significantly above the industry median, indicating strong short-term liquidity. However, the company has no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. In terms of profitability, the company reported a net income of $21.25 million, but this was offset by an operating loss of $5.49 million, indicating that operational efficiency is a concern. The return on equity (ROE) is 1.56, and the return on assets (ROA) is 1.27, both of which are below the industry median, suggesting that the company is not generating strong returns relative to its equity and asset base. The company's operating cash flow is negative at -$10.19 million, and its free cash flow is -$21.80 million, indicating that the company is not generating sufficient cash from operations to fund its activities. The company's revenue is reported as $0.00, which is a significant concern and suggests that the company may not have a viable revenue stream at this time. The company's capital expenditure of -$2.50 million indicates that it is investing in its operations, but the lack of revenue raises questions about the sustainability of these investments. The company's geographic exposure is not disclosed, but the absence of revenue data suggests that the company may be in an early stage of development or may be facing significant market challenges. Looking ahead, the company's growth trajectory is uncertain. The lack of revenue and the negative operating cash flow suggest that the company may need to secure additional financing to continue operations. The company's liquidity position is currently strong, with a current ratio of 4.75, but the negative free cash flow indicates that this may not be sustainable in the long term. The company's risk assessment indicates low liquidity and dilution risk, but the absence of revenue and the negative operating cash flow suggest that the company may face significant financial challenges in the future. Recent events and filings do not indicate any immediate liquidity or dilution risks, but the company's financial performance raises concerns about its long-term viability. The company's capital structure is currently debt-free, but the need for additional financing may lead to increased leverage in the future. The company's profitability metrics are weak, and the lack of revenue suggests that the company may need to pivot its business model or secure new revenue streams to remain competitive.
Business. Scienture Holdings Inc is a company in the Pharmaceuticals & Medical Research industry, primarily engaged in the development and commercialization of medical technologies and pharmaceutical products.
Classification. Scienture is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.
- The company has a strong liquidity position with a current ratio of 4.75, but this is offset by negative operating and free cash flows.
- The company's profitability metrics, including ROE and ROA, are below the industry median, indicating weak returns.
- The company's revenue is reported as $0.00, which is a significant concern and suggests that the company may not have a viable revenue stream.
- The company's capital structure is currently debt-free, but the need for additional financing may lead to increased leverage in the future.
- The company's growth trajectory is uncertain, and the lack of revenue and negative cash flows suggest that the company may face significant financial challenges.
- --
- ## RATIONALES
- ```json
- No immediate filing-based liquidity or dilution flags were detected.